Literature DB >> 18472842

Cytokines in inflammatory bowel disease.

P L Beck1, J L Wallace.   

Abstract

Over the past decade, much has been learned regarding the role of various cytokines in the pathogenesis of inflammatory bowel disease. Several cytokine 'knockout' models in mice have been shown to develop colitis, while alterations in the production of various cytokines has been documented in human Crohn's disease and ulcerative colitis. In recent years, attempts have been made to treat these diseases through modulation of cytokine production or action. This review focuses on the cytokines that have been implicated in the pathogenesis of inflammatory bowel disease. The evidence for and against a role for particular cytokines in intestinal inflammation is reviewed, as is the experimental and clinical data suggesting that cytokines are rational targets for the development of new therapies.

Entities:  

Year:  1997        PMID: 18472842      PMCID: PMC2365859          DOI: 10.1080/09629359791785

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  65 in total

1.  Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease.

Authors:  S Schreiber; T Heinig; U Panzer; R Reinking; A Bouchard; P D Stahl; A Raedler
Journal:  Gastroenterology       Date:  1995-01       Impact factor: 22.682

2.  Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6.

Authors:  K Mitsuyama; A Toyonaga; E Sasaki; O Ishida; H Ikeda; O Tsuruta; K Harada; H Tateishi; T Nishiyama; K Tanikawa
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

3.  Differential effects of anti-inflammatory cytokines (IL-4, IL-10 and IL-13) on tumoricidal and chemotactic properties of human monocytes induced by monocyte chemotactic and activating factor.

Authors:  S Yano; S Sone; Y Nishioka; N Mukaida; K Matsushima; T Ogura
Journal:  J Leukoc Biol       Date:  1995-02       Impact factor: 4.962

4.  Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease.

Authors:  B Davidsen; P Munkholm; P Schlichting; O H Nielsen; H Krarup; V Bonnevie-Nielsen
Journal:  Aliment Pharmacol Ther       Date:  1995-02       Impact factor: 8.171

5.  Cytokines in Crohn's colitis.

Authors:  M E Sher; A J D'Angelo; T A Stein; B Bailey; G Burns; L Wise
Journal:  Am J Surg       Date:  1995-01       Impact factor: 2.565

6.  Decreased mucosal interleukin-4 (IL-4) production in gut inflammation.

Authors:  R Karttunnen; E J Breese; J A Walker-Smith; T T MacDonald
Journal:  J Clin Pathol       Date:  1994-11       Impact factor: 3.411

7.  Intraluminal colonic release of immunoreactive tumour necrosis factor in chronic ulcerative colitis.

Authors:  F Casellas; M Papo; F Guarner; M Antolín; J R Armengol; J R Malagelada
Journal:  Clin Sci (Lond)       Date:  1994-10       Impact factor: 6.124

8.  Transdermal nicotine as maintenance therapy for ulcerative colitis.

Authors:  G A Thomas; J Rhodes; V Mani; G T Williams; R G Newcombe; M A Russell; C Feyerabend
Journal:  N Engl J Med       Date:  1995-04-13       Impact factor: 91.245

9.  Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation.

Authors:  V Casini-Raggi; L Kam; Y J Chong; C Fiocchi; T T Pizarro; F Cominelli
Journal:  J Immunol       Date:  1995-03-01       Impact factor: 5.422

10.  Interferon expression in Crohn's disease patients: increased interferon-gamma and -alpha mRNA in the intestinal lamina propria mononuclear cells.

Authors:  S Fais; M R Capobianchi; M Silvestri; F Mercuri; F Pallone; F Dianzani
Journal:  J Interferon Res       Date:  1994-10
View more
  15 in total

1.  Modulation of cytokine release from colonic explants by bacterial antigens in inflammatory bowel disease.

Authors:  S Dionne; S Laberge; C Deslandres; E G Seidman
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

2.  Glucocorticoid-induced tumour necrosis factor receptor family-related receptor signalling exacerbates hapten-induced colitis by CD4+ T cells.

Authors:  Sun K Lee; Beom K Choi; Young H Kim; Woo J Kang; Kwang H Kim; Shimon Sakaguchi; Jae H Suh; Tae Y Kim; Byoung S Kwon
Journal:  Immunology       Date:  2006-12       Impact factor: 7.397

Review 3.  Overview of cytokines and nitric oxide involvement in immuno-pathogenesis of inflammatory bowel diseases.

Authors:  Imene Soufli; Ryma Toumi; Hayet Rafa; Chafia Touil-Boukoffa
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-08-06

4.  Tumour necrosis factor-alpha and leukotriene B(4) mediate the neutrophil migration in immune inflammation.

Authors:  C Canetti; J S Silva; S H Ferreira; F Q Cunha
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

5.  Selective MyD88-dependent pathway inhibition by the cyanobacterial natural product malyngamide F acetate.

Authors:  Francisco A Villa; Kelly Lieske; Lena Gerwick
Journal:  Eur J Pharmacol       Date:  2009-12-16       Impact factor: 4.432

Review 6.  Roles of hepatocyte growth factor activator (HGFA) and its inhibitor HAI-1 in the regeneration of injured gastrointestinal mucosa.

Authors:  Hiroshi Itoh; Hiroaki Kataoka
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

7.  The puzzling inflammatory bowel disease: growing interest for mediators of inflammation.

Authors:  F J Zijlstra
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

8.  Resveratrol modulates cytokine-induced Jak/STAT activation more efficiently than 5-aminosalicylic acid: an in vitro approach.

Authors:  Diana Serra; Ana T Rufino; Alexandrina F Mendes; Leonor M Almeida; Teresa C P Dinis
Journal:  PLoS One       Date:  2014-10-01       Impact factor: 3.240

9.  Anti-inflammatory Effects of Herbal Preparations STW5 and STW5-II in Cytokine-Challenged Normal Human Colon Cells.

Authors:  Mathias Schneider; Thomas Efferth; Heba Abdel-Aziz
Journal:  Front Pharmacol       Date:  2016-10-26       Impact factor: 5.810

10.  Therapeutic effects of mouse bone marrow-derived clonal mesenchymal stem cells in a mouse model of inflammatory bowel disease.

Authors:  Jin Seok Park; Tac-Ghee Yi; Jong-Min Park; Young Min Han; Jun-Hyung Kim; Dong-Hee Shin; Seon Ji Tak; Kyuheon Lee; Youn Sook Lee; Myung-Shin Jeon; Ki-Baik Hahm; Sun U Song; Seok Hee Park
Journal:  J Clin Biochem Nutr       Date:  2015-10-21       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.